Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 59 EP applications Andrew George Smith has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after September 21, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12723323

NOVEL IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF ARTHRITIS

IPC classification:
A61K 31/4439, C07D 403/12, C07D 403/04, A61P 19/02
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12727984

PYRAZOLE DERIVATIVES USEFUL AS ALDOSTERONE SYNTHASE INHIBITORS

IPC classification:
A61K 31/416, C07D 231/56, C07D 231/54, A61P 13/00, A61P 9/00, A61P 5/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12735409

(THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

IPC classification:
A61K 31/55, C07D 498/04, A61P 25/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP12748334

NOVEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVE USEFUL FOR THE TREATMENT OF DIABETES

IPC classification:
A61K 31/4709, A61K 31/381, C07D 409/06
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12756856

(THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

IPC classification:
A61K 31/5513, C07D 498/04, A61P 25/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP12775406

SELECTIVE ANDROGEN RECEPTOR MODULATORS

IPC classification:
A61K 31/351, A61K 31/341, A61K 31/136, C07D 309/14, C07D 307/22, C07C 255/58, A61P 21/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP12783804

COMBINATION THERAPY FOR OVARIAN CANCER

IPC classification:
A61K 31/7068, A61K 31/555, A61K 31/437, A61P 35/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12795315

SPIROTHIENOPYRAN- PIPERIDINE DERIVATIVES AS ORL-1 RECEPTOR ANTAGONISTS FOR THEIR USE IN THE TREATMENT OF ALCOHOL DEPENDENCE AND ABUSE

IPC classification:
A61K 31/435, A61P 25/32
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP12701824

SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

IPC classification:
A61K 31/5517, C07D 487/04, A61P 25/20
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13701550

PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT - 2 INHIBITORS

IPC classification:
A61K 31/445, C07D 417/04, C07D 401/04, C07D 295/03, C07D 277/64, C07D 213/24, C07D 213/06, C07D 211/44, C07D 211/42, A61P 3/06
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13703234

BENZYL SULFONAMIDE DERIVATIVES USEFUL AS MOGAT - 2 INHIBITORS

IPC classification:
A61K 31/4402, C07D 213/65, C07D 213/64, C07C 311/05, A61P 3/10
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13702564

NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS

IPC classification:
A61K 31/5375, C07D 295/04, C07D 295/03, C07D 265/30, A61P 3/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12741192

NOTCH PATHWAY SIGNALING INHIBITOR COMPOUND

IPC classification:
A61K 38/05, C07K 5/062, C07D 471/04, C07D 401/04, A61P 35/02, A61P 35/00
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11808065

NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS

IPC classification:
A61P 29/00, A61K 31/4168, C07D 233/88
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13722231

PYRAZOLE COMPOUNDS AS SGLT1 INHIBITORS

IPC classification:
A61K 31/438, A61K 31/4155, C07D 487/10, C07D 471/10, A61P 3/10
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13729215

INHIBITOR OF JAK1 AND JAK2

IPC classification:
A61K 31/4155, C07D 471/04, A61P 35/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13734249

DIMETHYL-BENZOIC ACID COMPOUNDS

IPC classification:
A61K 31/4709, A61K 31/445, A61K 31/4025, A61K 31/402, C07D 401/04, C07D 211/46, C07D 211/42, C07D 207/08, A61P 29/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13734248

PHENOXYETHYL PIPERIDINE COMPOUNDS

IPC classification:
A61K 31/45, C07D 211/60, A61P 29/00, A61P 19/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP13789443

NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS

IPC classification:
C07D 319/00, C07D 311/00, C07D 309/00, C07D 307/00, C07D 273/00, C07D 263/00, C07D 217/00, C07D 207/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP14701636

(THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

IPC classification:
A61K 31/55, C07D 498/04, A61P 25/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP12701207

IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUND AND ITS USE AS PI3 KINASE / MTOR DUAL INHIBITOR

IPC classification:
A61P 35/00, A61K 31/4745, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14712966

CDC7 Inhibitors

IPC classification:
C07D 403/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14727692

PHENOXYETHYL DIHYDRO-1H-ISOQUINOLINE COMPOUNDS

IPC classification:
A61P 29/00, A61K 31/472, C07D 217/26
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP14732756

3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS

IPC classification:
A61P 25/18, A61P 25/16, A61K 31/472, C07D 217/16
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14796332

1 -(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS

IPC classification:
A61P 3/10, A61K 31/438, C07D 487/10
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14793753

GLUCOPYRANOSYL-SUBSTITUTED INDOLE-UREA DERIVATIVES AND THEIR USE AS SGLT INHIBITORS

IPC classification:
A61K 31/7042, C07H 19/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14800188

PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS

IPC classification:
A61P 35/00, A61K 31/519, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14802974

4-{4-[(1 E)-4-(2,9-DIAZASPIRO[5.5]UNDEC-2-YL)BUT-1 -EN-1 -YL]-2-METHYLBENZYL}-5-(PROPAN-2-YL)-1 H-PYRAZOL-3-YL BETA-D- GLUCOPYRANOSIDE ACETATE

IPC classification:
A61P 3/10, A61K 31/7056, C07H 17/02
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14802755

SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR

IPC classification:
A61P 3/00, A61K 31/506, C07D 401/06
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14809734

NOVEL DGAT2 INHIBITORS

IPC classification:
A61P 3/00, A61P 9/00, A61K 31/506, C07D 239/42
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14816539

A NOVEL TRIAZOLO-PYRIDINE COMPOUND

IPC classification:
A61P 5/00, A61K 31/4196, C07D 249/18
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14827908

DIMETHYLBENZOIC ACID COMPOUNDS

IPC classification:
C07D 405/02, C07D 401/12, C07C 215/52, C07D 213/81, C07C 235/42, C07C 233/81
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14827909

FLUOROPHENYL PYRAZOL COMPOUNDS

IPC classification:
A61P 3/04, A61K 31/45, C07D 401/12, C07D 231/20, C07D 403/12
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14827907

PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS

IPC classification:
A61P 19/02, A61K 31/45, A61K 31/445, A61K 31/438, C07D 211/60, C07D 209/52, C07D 207/16, C07D 221/20, C07D 221/04, C07D 217/26
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15702019

PHENYL-TRIAZOLO-PYRIDINE COMPOUNDS

IPC classification:
A61P 3/00, A61K 31/437, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP15700618

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

IPC classification:
A61P 3/10, A61K 31/437, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15749214

GPR142 AGONIST COMPOUNDS

IPC classification:
A61P 3/10, A61K 31/4178, A61K 31/4164, C07D 233/61, C07D 233/60, C07D 233/58
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15708638

COMBINATION THERAPY FOR CANCER

IPC classification:
A61P 35/00, A61K 31/506, A61K 39/395
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15767383

TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS

IPC classification:
A61P 21/00, A61P 21/06, A61P 19/08, A61P 5/26, A61K 31/4439
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP15777845

AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS

IPC classification:
A61P 43/00, A61P 35/00, A61K 31/4545, A61K 31/454, C07D 401/12, C07D 405/14, C07D 401/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP15798602

AURORA A KINASE INHIBITOR

IPC classification:
A61P 35/00, A61K 31/4545, C07D 401/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP15787859

NOVEL CARBOXYLIC ACID COMPOUNDS USEFUL FOR INHIBITING MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1

IPC classification:
A61P 29/00, A61K 31/445, C07D 211/62, C07C 235/40, C07D 401/12, C07D 401/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP15805705

1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS

IPC classification:
A61P 35/00, C07D 409/14, A61K 31/4725, C07D 409/12
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP15791432

NOVEL METHYL-PIPERIDINE COMPOUNDS USEFUL FOR INHIBITING MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1

IPC classification:
A61P 19/02, A61P 29/00, A61K 31/451, A61K 31/4709, A61K 31/506, C07D 211/62, C07D 401/04, C07D 405/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP15820005

ERK INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4436, C07D 495/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP15823869

THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS

IPC classification:
A61P 35/00, A61K 31/506, C07D 513/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16708823

PYRAZOLE COMPOUNDS

IPC classification:
A61P 3/04, A61K 31/506, C07D 403/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16758437

TETRAHYDROPYRANYL BENZAMIDE DERIVATIVES

IPC classification:
A61P 3/10, A61K 31/4245, A61K 31/4196, C07D 249/08, C07D 235/04, C07D 233/56, C07D 233/58, C07D 309/02, C07D 405/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16717802

GHRELIN O-ACYL TRANSFERASE INHIBITORS

IPC classification:
A61P 5/00, A61K 31/513, C07D 401/06
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16717800

GHRELIN O-ACYL TRANSFERASE INHIBITORS

IPC classification:
A61P 5/00, A61K 31/513, C07D 401/06
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16725725

NOVEL DGAT2 INHIBITORS

IPC classification:
A61P 9/00, A61K 31/506, C07D 403/12, C07D 401/12
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16732192

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE

IPC classification:
C07F 5/02, C07D 487/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16741742

NOTCH PATHWAY SIGNALING INHIBITOR COMPOUNDS

IPC classification:
A61P 35/00, A61P 27/16, A61K 31/55, C07D 471/14, C07D 487/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16745005

CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS

IPC classification:
A61P 35/00, A61K 31/4155, C07D 403/12
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16745954

7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS

IPC classification:
A61P 35/00, A61K 31/5365, C07D 519/00, C07D 498/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16750326

4-(3-PYRAZOLYLAMINO)-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS JAK1 INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4184, C07D 403/12
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16757513

INHIBITORS OF EZH2

IPC classification:
A61P 35/00, A61K 31/4365, C07D 495/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16766765

COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T

IPC classification:
A61P 17/06, A61P 37/00, A61K 31/438, C07D 495/20
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made
EP18169909

COMPOUNDS FOR USE IN THE TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS

IPC classification:
C07D 209/94, C07D 401/06, A61P 21/00, A61P 21/06, A61P 19/08, A61P 5/26, A61K 31/4439
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The application has been published

Please Sign in to use this feature